Newsroom

NEW YORK--(BUSINESS WIRE)--TPG RE Finance Trust, Inc. (NYSE: TRTX) (“TRTX” or the “Company”) today announced the Company’s Board of Directors declared a cash dividend of $0.3906 per share of 6.25% Series C Cumulative Redeemable Preferred Stock (the “Series C Preferred Stock”) for the second quarter of 2026. The Series C Preferred Stock dividend is payable on June 30, 2026 to preferred stockholders of record as of June 18, 2026. ABOUT TRTX TRTX is a commercial real estate finance company that or...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ: ENSG) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON THE ENSIGN GROUP, INC. (ENSG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On June 8, 2026, investment media group Hunterbrook Media publis...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Wealthfront Corporation (“Wealthfront” or the “Company”) (NASDAQ: WLTH) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON WEALTHFRONT CORPORATION (WLTH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On January 12, 2026, Wealthfront released its third quar...

SILICON SLOPES, Utah--(BUSINESS WIRE)--Domo (NASDAQ: DOMO) today announced that it will release financial results for its first quarter fiscal 2027 (ended April 30, 2026) after market close on Monday, June 15, 2026. The earnings release and conference call were previously scheduled for June 9, 2026. Domo anticipates that it will require additional time to complete its financial statements. As a result, the company intends to file an NT 10-Q with the Securities and Exchange Commission, in order...

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to three classes of notes issued by ACHD Trust 2026-DS1 (“ACHD 2026-DS1”), an ABS transaction collateralized by a pool of debt settlement (“DS”) fees associated with enrolled debts from a static pool of DS customers. ACHD 2026-DS1 will issue three classes of notes totaling $151.4 million. The transaction benefits from credit enhancement levels that are sufficient to withstand KBRA’s rating stresses. Credit enhancement is comprised of o...

MIAMI--(BUSINESS WIRE)--Lucky Strike Entertainment Corporation (NYSE: LUCK) announced today the promotion of Bobby Lavan to President and Chief Financial Officer....

RALEIGH, N.C.--(BUSINESS WIRE)--Opex Technologies (“Opex” or the “Company”), a leading Trusted Advisor for Technology Transformation Projects (TTP) and Strategic Leadership as a Service (SlaaS), today announced a strategic acquisition of Intellys Corporation (“Intellys”), a Dallas-based technology advisory firm specializing in multi-vendor support, carrier solutions, and managed IT services. The transaction marks a significant step toward building a national, scaled platform serving enterprise...

CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE, TSX: CDE) today announced that it will be added to the S&P MidCap 400 Index, effective prior to the open of trading on Monday, June 22, 2026. Coeur’s addition to the S&P MidCap 400 Index reflects the Company’s growth and transformation into the sector’s only all-North American senior precious metals producer and a leading global silver company following two recent successful acquisitions, and its commitment t...

RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer,...